{"id":"hydroxyurea","rwe":[],"_fda":{"id":"27c291c3-aa28-97af-e063-6394a90a6565","set_id":"1b42f2b4-3880-e7a9-e063-6294a90a5fd0","openfda":{"nui":["N0000180853","M0022315"],"unii":["X6Q56QN5QC"],"route":["ORAL"],"rxcui":["197797"],"spl_id":["27c291c3-aa28-97af-e063-6394a90a6565"],"brand_name":["HYDROXYUREA"],"spl_set_id":["1b42f2b4-3880-e7a9-e063-6294a90a5fd0"],"package_ndc":["51407-909-01"],"product_ndc":["51407-909"],"generic_name":["HYDROXYUREA"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_cs":["Urea [CS]"],"substance_name":["HYDROXYUREA"],"pharm_class_epc":["Antimetabolite [EPC]"],"manufacturer_name":["Golden State Medical Supply, Inc."],"application_number":["ANDA213438"],"original_packager_product_ndc":["69315-164"]},"version":"2","overdosage":["10 OVERDOSAGE Acute mucocutaneous toxicity has been reported in patients receiving hydroxyurea at dosages several times the therapeutic dose. Soreness, violet erythema, edema on palms and soles followed by scaling of hands and feet, severe generalized hyperpigmentation of the skin, and stomatitis have also been observed."],"references":["15 REFERENCES OSHA. http://www.osha.gov/SLTC/hazardousdrugs/index.html."],"description":["11 DESCRIPTION Hydroxyurea Capsules USP is an antimetabolite available for oral use as capsules containing 500 mg hydroxyurea, USP. Inactive ingredients include Colorants (D&C Yellow No. 10, FD&C Red No.3, FD&C Blue No.1), gelatin, lactose anhydrous, magnesium stearate and silicon dioxide and titanium dioxide. Hydroxyurea is a White or almost white, crystalline powder. It is hygroscopic and soluble in water, but practically insoluble in alcohol. The empirical formula is CH 4 N 2 O 2 and it has a molecular weight of 76.05. Its structural formula is: image description"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied Hydroxyurea capsules, USP is supplied as 500 mg capsules in HDPE bottles with heat induction Child Resistant Closures. Each bottle contains 100 capsules. The cap is opaque green, and the body is opaque light pink. The capsules are imprinted on both sections with “LP 164” in black ink (NDC 51407-909-01). 16.2 Storage Store at 20-25°C (68-77°F); excursions permitted to 15°C-30°C (59°F-86°F) [see USP Controlled Room Temperature]. Keep tightly closed. 16.3 Handling and Disposal Hydroxyurea capsules is a cytotoxic drug. Follow applicable special handling and disposal procedures [see References (15) ]. To decrease the risk of contact, advise caregivers to wear disposable gloves when handling hydroxyurea capsules or bottles containing hydroxyurea capsules. Wash hands with soap and water before and after contact with the bottle or capsules when handling hydroxyurea capsules. Do not open hydroxyurea capsules. Avoid exposure to crushed or opened capsules. If contact with crushed or opened capsules occurs on the skin, wash affected area immediately and thoroughly with soap and water. If contact with crushed or opened capsules occurs on the eye(s), the affected area should be flushed thoroughly with water or isotonic eyewash designated for that purpose for at least 15 minutes. If the powder from the capsule is spilled, immediately wipe it up with a damp disposable towel and discard in a closed container, such as a plastic bag; as should the empty capsules. The spill areas should then be cleaned three times using a detergent solution followed by clean water. Keep the medication away from children and pets. Contact your doctor for instructions on how to dispose of outdated capsules."],"effective_time":"20241125","adverse_reactions":["6 ADVERSE REACTIONS • Myelosuppression [see Warnings and Precautions (5.1) ] • Hemolytic anemia [see Warnings and Precautions (5.2) ] • Malignancies [see Warnings and Precautions (5.3) ] • Vasculitic toxicities [see Warnings and Precautions (5.5) ] • Risks with concomitant use of antiretroviral drugs [see Warnings and Precautions (5.7) ] • Radiation recall [see Warnings and Precautions (5.8) ] • Macrocytosis [see Warnings and Precautions (5.9) ] • Pulmonary Toxicity [see Warnings and Precautions (5.10) ] Most common adverse reactions (≥30%) are hematological, gastrointestinal symptoms, and anorexia. (6) To report SUSPECTED ADVERSE REACTIONS, contact Leading Pharma, LLC at 1-844-740-7500 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Postmarketing Experience The following adverse reactions have been identified during post-approval use of hydroxyurea capsules. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency. Reproductive System and Breast disorders: azoospermia, and oligospermia Gastrointestinal disorders: stomatitis, nausea, vomiting, diarrhea, and constipation Metabolism and Nutrition disorders: anorexia, tumor lysis syndrome Skin and subcutaneous tissue disorders: maculopapular rash, skin ulceration, cutaneous lupus erythematosus, dermatomyositis-like skin changes, peripheral and facial erythema, hyperpigmentation, nail hyperpigmentation, atrophy of skin and nails, scaling, violet papules, and alopecia Renal and urinary disorders: dysuria, elevations in serum uric acid, blood urea nitrogen (BUN), and creatinine levels Nervous system disorders: headache, dizziness, drowsiness, disorientation, hallucinations, and convulsions General Disorders: fever, chills, malaise, edema, and asthenia Hepatobiliary disorders: elevation of hepatic enzymes, cholestasis, and hepatitis Respiratory disorders: diffuse pulmonary infiltrates, dyspnea, and pulmonary fibrosis, interstitial lung disease, pneumonitis, alveolitis, allergic alveolitis and cough Immune disorders: systemic lupus erythematosus Hypersensitivity: Drug-induced fever (pyrexia) (>39°C, >102°F) requiring hospitalization has been reported concurrently with gastrointestinal, pulmonary, musculoskeletal, hepatobiliary, dermatological or cardiovascular manifestations. Onset typically occurred within 6 weeks of initiation and resolved upon discontinuation of hydroxyurea. Upon re-administration fever re- occurred typically within 24 hours. Blood and lymphatic system disorders: hemolytic anemia Adverse reactions observed with combined hydroxyurea and irradiation therapy are similar to those reported with the use of hydroxyurea or radiation treatment alone. These effects primarily include bone marrow depression (anemia and leukopenia), gastric irritation, and mucositis. Almost all patients receiving an adequate course of combined hydroxyurea and irradiation therapy will demonstrate concurrent leukopenia. Platelet depression (<100,000 cells/mm3) has occurred in the presence of marked leukopenia. Hydroxyurea capsules may potentiate some adverse reactions usually seen with irradiation alone, such as gastric distress and mucositis.","6.1 Postmarketing Experience The following adverse reactions have been identified during post-approval use of hydroxyurea capsules. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency. Reproductive System and Breast disorders: azoospermia, and oligospermia Gastrointestinal disorders: stomatitis, nausea, vomiting, diarrhea, and constipation Metabolism and Nutrition disorders: anorexia, tumor lysis syndrome Skin and subcutaneous tissue disorders: maculopapular rash, skin ulceration, cutaneous lupus erythematosus, dermatomyositis-like skin changes, peripheral and facial erythema, hyperpigmentation, nail hyperpigmentation, atrophy of skin and nails, scaling, violet papules, and alopecia Renal and urinary disorders: dysuria, elevations in serum uric acid, blood urea nitrogen (BUN), and creatinine levels Nervous system disorders: headache, dizziness, drowsiness, disorientation, hallucinations, and convulsions General Disorders: fever, chills, malaise, edema, and asthenia Hepatobiliary disorders: elevation of hepatic enzymes, cholestasis, and hepatitis Respiratory disorders: diffuse pulmonary infiltrates, dyspnea, and pulmonary fibrosis, interstitial lung disease, pneumonitis, alveolitis, allergic alveolitis and cough Immune disorders: systemic lupus erythematosus Hypersensitivity: Drug-induced fever (pyrexia) (>39°C, >102°F) requiring hospitalization has been reported concurrently with gastrointestinal, pulmonary, musculoskeletal, hepatobiliary, dermatological or cardiovascular manifestations. Onset typically occurred within 6 weeks of initiation and resolved upon discontinuation of hydroxyurea. Upon re-administration fever re- occurred typically within 24 hours. Blood and lymphatic system disorders: hemolytic anemia Adverse reactions observed with combined hydroxyurea and irradiation therapy are similar to those reported with the use of hydroxyurea or radiation treatment alone. These effects primarily include bone marrow depression (anemia and leukopenia), gastric irritation, and mucositis. Almost all patients receiving an adequate course of combined hydroxyurea and irradiation therapy will demonstrate concurrent leukopenia. Platelet depression (<100,000 cells/mm3) has occurred in the presence of marked leukopenia. Hydroxyurea capsules may potentiate some adverse reactions usually seen with irradiation alone, such as gastric distress and mucositis."],"contraindications":["4 CONTRAINDICATIONS Hydroxyurea capsules is contraindicated in patients who have demonstrated a previous hypersensitivity to hydroxyurea or any other component of the formulation. • In patients who have demonstrated a previous hypersensitivity to hydroxyurea or any other component of its formulation. (4)"],"drug_interactions":["7 DRUG INTERACTIONS Antiretroviral drugs (7.1) Laboratory Test Interference. (7.2) 7.1 Increased Toxicity with Concomitant Use of Antiretroviral Drugs Pancreatitis In patients with HIV infection during therapy with hydroxyurea and didanosine, with or without stavudine, fatal and nonfatal pancreatitis have occurred. Hydroxyurea is not indicated for the treatment of HIV infection; however, if patients with HIV infection are treated with hydroxyurea, and in particular, in combination with didanosine and/or stavudine, close monitoring for signs and symptoms of pancreatitis is recommended. Permanently discontinue therapy with hydroxyurea in patients who develop signs and symptoms of pancreatitis. Hepatotoxicity Hepatotoxicity and hepatic failure resulting in death have been reported during postmarketing surveillance in patients with HIV infection treated with hydroxyurea and other antiretroviral drugs. Fatal hepatic events were reported most often in patients treated with the combination of hydroxyurea, didanosine, and stavudine. Avoid this combination. Peripheral Neuropathy Peripheral neuropathy, which was severe in some cases, has been reported in patients with HIV infection receiving hydroxyurea in combination with antiretroviral drugs, including didanosine, with or without stavudine. 7.2 Laboratory Test Interference Interference with Uric Acid, Urea, or Lactic Acid Assays Studies have shown that there is an analytical interference of hydroxyurea with the enzymes (urease, uricase, and lactate dehydrogenase) used in the determination of urea, uric acid, and lactic acid, rendering falsely elevated results of these in patients treated with hydroxyurea. Interference with Continuous Glucose Monitoring Systems Hydroxyurea may falsely elevate sensor glucose results from certain continuous glucose monitoring (CGM) systems and may lead to hypoglycemia if sensor glucose results are relied upon to dose insulin. If a patient using a CGM is to be prescribed hydroxyurea, consult with the CGM prescriber about alternative glucose monitoring methods.","7.1 Increased Toxicity with Concomitant Use of Antiretroviral Drugs Pancreatitis In patients with HIV infection during therapy with hydroxyurea and didanosine, with or without stavudine, fatal and nonfatal pancreatitis have occurred. Hydroxyurea is not indicated for the treatment of HIV infection; however, if patients with HIV infection are treated with hydroxyurea, and in particular, in combination with didanosine and/or stavudine, close monitoring for signs and symptoms of pancreatitis is recommended. Permanently discontinue therapy with hydroxyurea in patients who develop signs and symptoms of pancreatitis. Hepatotoxicity Hepatotoxicity and hepatic failure resulting in death have been reported during postmarketing surveillance in patients with HIV infection treated with hydroxyurea and other antiretroviral drugs. Fatal hepatic events were reported most often in patients treated with the combination of hydroxyurea, didanosine, and stavudine. Avoid this combination. Peripheral Neuropathy Peripheral neuropathy, which was severe in some cases, has been reported in patients with HIV infection receiving hydroxyurea in combination with antiretroviral drugs, including didanosine, with or without stavudine.","7.2 Laboratory Test Interference Interference with Uric Acid, Urea, or Lactic Acid Assays Studies have shown that there is an analytical interference of hydroxyurea with the enzymes (urease, uricase, and lactate dehydrogenase) used in the determination of urea, uric acid, and lactic acid, rendering falsely elevated results of these in patients treated with hydroxyurea. Interference with Continuous Glucose Monitoring Systems Hydroxyurea may falsely elevate sensor glucose results from certain continuous glucose monitoring (CGM) systems and may lead to hypoglycemia if sensor glucose results are relied upon to dose insulin. If a patient using a CGM is to be prescribed hydroxyurea, consult with the CGM prescriber about alternative glucose monitoring methods."],"recent_major_changes":["RECENT MAJOR CHANGES Warnings and Precautions, Laboratory Test Interference (5.11) 11/2023 Drug Interactions, Laboratory Test Interference (7.2) 11/2023"],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action The precise mechanism by which hydroxyurea produces its antineoplastic effects cannot, at present, be described. However, the reports of various studies in tissue culture in rats and humans lend support to the hypothesis that hydroxyurea causes an immediate inhibition of DNA synthesis by acting as a ribonucleotide reductase inhibitor, without interfering with the synthesis of ribonucleic acid or of protein. This hypothesis explains why, under certain conditions, hydroxyurea may induce teratogenic effects. Three mechanisms of action have been postulated for the increased effectiveness of concomitant use of hydroxyurea therapy with irradiation on squamous cell (epidermoid) carcinomas of the head and neck. In vitro studies utilizing Chinese hamster cells suggest that hydroxyurea (1) is lethal to normally radioresistant S-stage cells, and (2) holds other cells of the cell cycle in the G1 or pre-DNA synthesis stage where they are most susceptible to the effects of irradiation. The third mechanism of action has been theorized on the basis of in vitro studies of HeLa cells. It appears that hydroxyurea, by inhibition of DNA synthesis, hinders the normal repair process of cells damaged but not killed by irradiation, thereby decreasing their survival rate; RNA and protein syntheses have shown no alteration. 12.3 Pharmacokinetics Absorption Following oral administration of hydroxyurea capsules, hydroxyurea reaches peak plasma concentrations in 1 to 4 hours. Mean peak plasma concentrations and AUCs increase more than proportionally with increase of dose. There are no data on the effect of food on the absorption of hydroxyurea. Distribution Hydroxyurea distributes throughout the body with a volume of distribution approximating total body water. Hydroxyurea concentrates in leukocytes and erythrocytes. Metabolism Up to 60% of an oral dose undergoes conversion through saturable hepatic metabolism and a minor pathway of degradation by urease found in intestinal bacteria. Excretion In patients with sickle cell anemia, the mean cumulative urinary recovery of hydroxyurea was about 40% of the administered dose. Specific Populations Renal Impairment The effect of renal impairment on the pharmacokinetics of hydroxyurea was assessed in adult patients with sickle cell disease and renal impairment. Patients with normal renal function (creatinine clearance [CrCl] >80 mL/min), mild (CrCl 50 to 80 mL/min), moderate (CrCl = 30-<50 mL/min), or severe (<30 mL/min) renal impairment received a single oral dose of 15 mg/kg hydroxyurea. Patients with ESRD received two doses of 15 mg/kg separated by 7 days; the first was given following a 4-hour hemodialysis session, the second prior to hemodialysis. The exposure to hydroxyurea (mean AUC) in patients with CrCl <60 mL/min and those with ESRD was 64% higher than in patients with normal renal function (CrCl >60 mL/min). Reduce the dose of hydroxyurea capsules when it is administered to patients with creatinine clearance of <60 mL/min or with ESRD following hemodialysis [see Dosage and Administration (2.3 ) and Use in Specific Populations (8.6) ].","12.1 Mechanism of Action The precise mechanism by which hydroxyurea produces its antineoplastic effects cannot, at present, be described. However, the reports of various studies in tissue culture in rats and humans lend support to the hypothesis that hydroxyurea causes an immediate inhibition of DNA synthesis by acting as a ribonucleotide reductase inhibitor, without interfering with the synthesis of ribonucleic acid or of protein. This hypothesis explains why, under certain conditions, hydroxyurea may induce teratogenic effects. Three mechanisms of action have been postulated for the increased effectiveness of concomitant use of hydroxyurea therapy with irradiation on squamous cell (epidermoid) carcinomas of the head and neck. In vitro studies utilizing Chinese hamster cells suggest that hydroxyurea (1) is lethal to normally radioresistant S-stage cells, and (2) holds other cells of the cell cycle in the G1 or pre-DNA synthesis stage where they are most susceptible to the effects of irradiation. The third mechanism of action has been theorized on the basis of in vitro studies of HeLa cells. It appears that hydroxyurea, by inhibition of DNA synthesis, hinders the normal repair process of cells damaged but not killed by irradiation, thereby decreasing their survival rate; RNA and protein syntheses have shown no alteration.","12.3 Pharmacokinetics Absorption Following oral administration of hydroxyurea capsules, hydroxyurea reaches peak plasma concentrations in 1 to 4 hours. Mean peak plasma concentrations and AUCs increase more than proportionally with increase of dose. There are no data on the effect of food on the absorption of hydroxyurea. Distribution Hydroxyurea distributes throughout the body with a volume of distribution approximating total body water. Hydroxyurea concentrates in leukocytes and erythrocytes. Metabolism Up to 60% of an oral dose undergoes conversion through saturable hepatic metabolism and a minor pathway of degradation by urease found in intestinal bacteria. Excretion In patients with sickle cell anemia, the mean cumulative urinary recovery of hydroxyurea was about 40% of the administered dose. Specific Populations Renal Impairment The effect of renal impairment on the pharmacokinetics of hydroxyurea was assessed in adult patients with sickle cell disease and renal impairment. Patients with normal renal function (creatinine clearance [CrCl] >80 mL/min), mild (CrCl 50 to 80 mL/min), moderate (CrCl = 30-<50 mL/min), or severe (<30 mL/min) renal impairment received a single oral dose of 15 mg/kg hydroxyurea. Patients with ESRD received two doses of 15 mg/kg separated by 7 days; the first was given following a 4-hour hemodialysis session, the second prior to hemodialysis. The exposure to hydroxyurea (mean AUC) in patients with CrCl <60 mL/min and those with ESRD was 64% higher than in patients with normal renal function (CrCl >60 mL/min). Reduce the dose of hydroxyurea capsules when it is administered to patients with creatinine clearance of <60 mL/min or with ESRD following hemodialysis [see Dosage and Administration (2.3 ) and Use in Specific Populations (8.6) ]."],"indications_and_usage":["1 INDICATIONS AND USAGE Hydroxyurea capsules, USP is indicated for the treatment of: Resistant chronic myeloid leukemia. Locally advanced squamous cell carcinomas of the head and neck (excluding the lip) in combination with chemoradiation. Hydroxyurea capsules, USP is an antimetabolite indicated for the treatment of: • Resistant chronic myeloid leukemia. (1) • Locally advanced squamous cell carcinomas of the head and neck, (excluding lip) in combination with concurrent chemoradiation. (1)"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Myelosuppression: Do not give if bone marrow function is markedly depressed. Monitor blood counts at baseline and throughout treatment. Interrupt treatment and reduce dose as necessary. (5.1) Hemolytic anemia: Monitor blood counts throughout treatment. If hemolysis persists, discontinue Hydroxyurea. (5.2) Malignancies: Advise protection from sun exposure and monitor for secondary malignancies. ( 5.3) Embryo-Fetal toxicity: Can cause fetal harm. Advise of potential risk to a fetus and use of effective contraception. ( 5.4 , 8.1 , 8.3 ) Vasculitic toxicities: Discontinue hydroxyurea and initiate treatment if this occurs. (5.5) Live Vaccinations: Avoid live vaccine use in a patient taking hydroxyurea capsules. (5.6) Risks with concomitant use of antiretroviral drugs: Pancreatitis, hepatotoxicity, and neuropathy have occurred. Monitor for signs and symptoms in patients with HIV infection using antiretroviral drugs; discontinue hydroxyurea capsules and implement treatment. (5.7) Radiation recall: Monitor for skin erythema in patients who previously received radiation and manage symptomatically. (5.8) 5.1 Myelosuppression s ion Hydroxyurea causes severe myelosuppression. Treatment with hydroxyurea should not be initiated if bone marrow function is markedly depressed. Bone marrow suppression may occur, and leukopenia is generally its first and most common manifestation. Thrombocytopenia and anemia occur less often and are seldom seen without a preceding leukopenia. Bone marrow depression is more likely in patients who have previously received radiotherapy or cytotoxic cancer chemotherapeutic agents; use hydroxyurea cautiously in such patients. Evaluate hematologic status prior to and during treatment with hydroxyurea capsules. Provide supportive care and modify dose or discontinue hydroxyurea as needed. Recovery from myelosuppression is usually rapid when therapy is interrupted. 5.2 Hemolytic Anemia Cases of hemolytic anemia in patients treated with hydroxyurea for myeloproliferative diseases have been reported [see Adverse Reactions (6.1) ]. Patients who develop acute jaundice or hematuria in the presence of persistent or worsening of anemia should have laboratory tests evaluated for hemolysis (e.g., measurement of serum lactate dehydrogenase, haptoglobin, reticulocyte, unconjugated bilirubin levels, urinalysis, and direct and indirect antiglobulin [Coombs] tests). In the setting of confirmed diagnosis of hemolytic anemia and in the absence of other causes, discontinue hydroxyurea. 5.3 Malignancies Hydroxyurea is a human carcinogen. In patients receiving long-term hydroxyurea for myeloproliferative disorders, secondary leukemia has been reported. Skin cancer has also been reported in patients receiving long-term hydroxyurea. Advise protection from sun exposure and monitor for the development of secondary malignancies. 5.4 Embryo-Fetal Toxicity Based on the mechanism of action and findings in animals, hydroxyurea can cause fetal harm when administered to a pregnant woman. Hydroxyurea was embryotoxic and teratogenic in rats and rabbits at doses 0.8 times and 0.3 times, respectively, the maximum recommended human daily dose on a mg/m 2 basis. Advise pregnant women of the potential risk to a fetus [see Use in Specific Populations (8.1) ]. Advise females of reproductive potential to use effective contraception during and after treatment with hydroxyurea capsules for at least 6 months after therapy. Advise males of reproductive potential to use effective contraception during and after treatment with hydroxyurea capsules for at least 1 year after therapy [see Use in Specific Populations (8.1 , 8.3) ]. 5.5 Vasculitic Toxicities Cutaneous vasculitic toxicities, including vasculitic ulcerations and gangrene, have occurred in patients with myeloproliferative disorders during therapy with hydroxyurea. These vasculitic toxicities were reported most often in patients with a history of, or currently receiving, interferon therapy. If cutaneous vasculitic ulcers occur, institute treatment and discontinue hydroxyurea capsules. 5.6 Live Vaccinations Avoid use of live vaccine in patients taking hydroxyurea capsules. Concomitant use of hydroxyurea capsules with a live virus vaccine may potentiate the replication of the virus and/or may increase the adverse reaction of the vaccine because normal defense mechanisms may be suppressed by hydroxyurea capsules. Vaccination with live vaccines in a patient receiving hydroxyurea capsules may result in severe infection. Patient’s antibody response to vaccines may be decreased. Consider consultation with a specialist. 5.7 Risks with Concomitant Use of Antiretroviral Drugs Pancreatitis, hepatotoxicity, and peripheral neuropathy have occurred when hydroxyurea was administered concomitantly with antiretroviral drugs, including didanosine and stavudine [see Drug Interactions (7.1) ]. 5.8 Radiation Recall Patients who have received irradiation therapy in the past may have an exacerbation of post-irradiation erythema. Monitor for skin erythema in patients who previously received radiation and manage symptomatically. 5.9 Macrocytosis Hydroxyurea capsules may cause macrocytosis, which is self-limiting, and is often seen early in the course of treatment. The morphologic change resembles pernicious anemia, but is not related to vitamin B 12 or folic acid deficiency. This may mask the diagnosis of pernicious anemia. Prophylactic administration of folic acid is recommended. 5.10 Pulmonary Toxicity Interstitial lung disease including pulmonary fibrosis, lung infiltration, pneumonitis, and alveolitis/allergic alveolitis (including fatal cases) have been reported in patients treated for myeloproliferative neoplasm. Monitor patients developing pyrexia, cough, dyspnea, or other respiratory symptoms frequently, investigate and treat promptly. Discontinue hydroxyurea and manage with corticosteroids [ see Adverse Reactions (6.1) ]. 5.11 Laboratory Test Interference Interference with Uric Acid, Urea, or Lactic Acid Assays is possible, rendering falsely elevated results of these in patients treated with hydroxyurea [see Drug Interactions (7.2) ]. Hydroxyurea may falsely elevate sensor glucose results from certain continuous glucose monitoring (CGM) systems and may lead to hypoglycemia if sensor glucose results are relied upon to dose insulin. If a patient using a CGM is to be prescribed hydroxyurea, consult with the CGM prescriber about alternative glucose monitoring methods [see Drug Interactions (7.2) ].","5.1 Myelosuppression s ion Hydroxyurea causes severe myelosuppression. Treatment with hydroxyurea should not be initiated if bone marrow function is markedly depressed. Bone marrow suppression may occur, and leukopenia is generally its first and most common manifestation. Thrombocytopenia and anemia occur less often and are seldom seen without a preceding leukopenia. Bone marrow depression is more likely in patients who have previously received radiotherapy or cytotoxic cancer chemotherapeutic agents; use hydroxyurea cautiously in such patients. Evaluate hematologic status prior to and during treatment with hydroxyurea capsules. Provide supportive care and modify dose or discontinue hydroxyurea as needed. Recovery from myelosuppression is usually rapid when therapy is interrupted.","5.2 Hemolytic Anemia Cases of hemolytic anemia in patients treated with hydroxyurea for myeloproliferative diseases have been reported [see Adverse Reactions (6.1) ]. Patients who develop acute jaundice or hematuria in the presence of persistent or worsening of anemia should have laboratory tests evaluated for hemolysis (e.g., measurement of serum lactate dehydrogenase, haptoglobin, reticulocyte, unconjugated bilirubin levels, urinalysis, and direct and indirect antiglobulin [Coombs] tests). In the setting of confirmed diagnosis of hemolytic anemia and in the absence of other causes, discontinue hydroxyurea.","5.3 Malignancies Hydroxyurea is a human carcinogen. In patients receiving long-term hydroxyurea for myeloproliferative disorders, secondary leukemia has been reported. Skin cancer has also been reported in patients receiving long-term hydroxyurea. Advise protection from sun exposure and monitor for the development of secondary malignancies.","5.4 Embryo-Fetal Toxicity Based on the mechanism of action and findings in animals, hydroxyurea can cause fetal harm when administered to a pregnant woman. Hydroxyurea was embryotoxic and teratogenic in rats and rabbits at doses 0.8 times and 0.3 times, respectively, the maximum recommended human daily dose on a mg/m 2 basis. Advise pregnant women of the potential risk to a fetus [see Use in Specific Populations (8.1) ]. Advise females of reproductive potential to use effective contraception during and after treatment with hydroxyurea capsules for at least 6 months after therapy. Advise males of reproductive potential to use effective contraception during and after treatment with hydroxyurea capsules for at least 1 year after therapy [see Use in Specific Populations (8.1 , 8.3) ].","5.5 Vasculitic Toxicities Cutaneous vasculitic toxicities, including vasculitic ulcerations and gangrene, have occurred in patients with myeloproliferative disorders during therapy with hydroxyurea. These vasculitic toxicities were reported most often in patients with a history of, or currently receiving, interferon therapy. If cutaneous vasculitic ulcers occur, institute treatment and discontinue hydroxyurea capsules.","5.6 Live Vaccinations Avoid use of live vaccine in patients taking hydroxyurea capsules. Concomitant use of hydroxyurea capsules with a live virus vaccine may potentiate the replication of the virus and/or may increase the adverse reaction of the vaccine because normal defense mechanisms may be suppressed by hydroxyurea capsules. Vaccination with live vaccines in a patient receiving hydroxyurea capsules may result in severe infection. Patient’s antibody response to vaccines may be decreased. Consider consultation with a specialist.","5.7 Risks with Concomitant Use of Antiretroviral Drugs Pancreatitis, hepatotoxicity, and peripheral neuropathy have occurred when hydroxyurea was administered concomitantly with antiretroviral drugs, including didanosine and stavudine [see Drug Interactions (7.1) ].","5.8 Radiation Recall Patients who have received irradiation therapy in the past may have an exacerbation of post-irradiation erythema. Monitor for skin erythema in patients who previously received radiation and manage symptomatically.","5.9 Macrocytosis Hydroxyurea capsules may cause macrocytosis, which is self-limiting, and is often seen early in the course of treatment. The morphologic change resembles pernicious anemia, but is not related to vitamin B 12 or folic acid deficiency. This may mask the diagnosis of pernicious anemia. Prophylactic administration of folic acid is recommended.","5.10 Pulmonary Toxicity Interstitial lung disease including pulmonary fibrosis, lung infiltration, pneumonitis, and alveolitis/allergic alveolitis (including fatal cases) have been reported in patients treated for myeloproliferative neoplasm. Monitor patients developing pyrexia, cough, dyspnea, or other respiratory symptoms frequently, investigate and treat promptly. Discontinue hydroxyurea and manage with corticosteroids [ see Adverse Reactions (6.1) ].","5.11 Laboratory Test Interference Interference with Uric Acid, Urea, or Lactic Acid Assays is possible, rendering falsely elevated results of these in patients treated with hydroxyurea [see Drug Interactions (7.2) ]. Hydroxyurea may falsely elevate sensor glucose results from certain continuous glucose monitoring (CGM) systems and may lead to hypoglycemia if sensor glucose results are relied upon to dose insulin. If a patient using a CGM is to be prescribed hydroxyurea, consult with the CGM prescriber about alternative glucose monitoring methods [see Drug Interactions (7.2) ]."],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Conventional long-term studies to evaluate the carcinogenic potential of hydroxyurea capsules have not been performed. However, intraperitoneal administration of 125 to 250 mg/kg hydroxyurea (about 0.6 to 1.2 times the maximum recommended human oral daily dose on a mg/m 2 basis) thrice weekly for 6 months to female rats increased the incidence of mammary tumors in rats surviving to 18 months compared to control. Hydroxyurea is mutagenic in vitro to bacteria, fungi, protozoa, and mammalian cells. Hydroxyurea is clastogenic in vitro (hamster cells, human lymphoblasts) and in vivo (SCE assay in rodents, mouse micronucleus assay). Hydroxyurea causes the transformation of rodent embryo cells to a tumorigenic phenotype. Hydroxyurea administered to male rats at 60 mg/kg/day (about 0.3 times the maximum recommended human daily dose on a mg/m 2 basis) produced testicular atrophy, decreased spermatogenesis, and significantly reduced their ability to impregnate females.","13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Conventional long-term studies to evaluate the carcinogenic potential of hydroxyurea capsules have not been performed. However, intraperitoneal administration of 125 to 250 mg/kg hydroxyurea (about 0.6 to 1.2 times the maximum recommended human oral daily dose on a mg/m 2 basis) thrice weekly for 6 months to female rats increased the incidence of mammary tumors in rats surviving to 18 months compared to control. Hydroxyurea is mutagenic in vitro to bacteria, fungi, protozoa, and mammalian cells. Hydroxyurea is clastogenic in vitro (hamster cells, human lymphoblasts) and in vivo (SCE assay in rodents, mouse micronucleus assay). Hydroxyurea causes the transformation of rodent embryo cells to a tumorigenic phenotype. Hydroxyurea administered to male rats at 60 mg/kg/day (about 0.3 times the maximum recommended human daily dose on a mg/m 2 basis) produced testicular atrophy, decreased spermatogenesis, and significantly reduced their ability to impregnate females."],"information_for_patients":["17 PATIENT COUNSELING INFORMATION There is a risk of myelosuppression. Monitoring blood counts weekly throughout the duration of therapy should be emphasized to patients taking hydroxyurea capsules . Advise patients to report signs and symptoms of infection or bleeding immediately. [see Warnings and Precautions (5.1) ]. Advise patients of the risk of hemolytic anemia. Advise patients that they will have blood tests to evaluate for this if they develop persistent anemia [see Warnings and Precautions (5.2) ]. Advise patients that there is a risk of cutaneous vasculitic toxicities and secondary malignancies including leukemia and skin cancers [see Warnings and Precautions (5.3, 5.5) ]. Advise females of reproductive potential of the potential risk to a fetus and to inform their healthcare provider of a known or suspected pregnancy. Advise females and males of reproductive potential to use contraception during and after treatment with hydroxyurea capsules [see Warnings and Precautions (5.4) and Use in Specific Populations (8.1 , 8.3) ]. Advise patients to inform their healthcare provider if they have received or are planning to receive vaccinations while taking hydroxyurea capsules as this may result in a severe infection [see Warnings and Precautions (5.6) ]. Advise females to discontinue breastfeeding during treatment with hydroxyurea capsules [see Use in Specific Populations (8.2) ]. Patients with HIV infection should contact their physician for signs and symptoms of pancreatitis, hepatic events, and peripheral neuropathy [see Warnings and Precautions (5.7) ]. Post-irradiation erythema can occur in patients who have received previous irradiation therapy [see Warnings and Precautions (5.8) ]. Advise patients of the symptoms of potential pulmonary toxicity and instruct them to seek prompt medical attention in the event of pyrexia, cough, dyspnea, or other respiratory symptoms [see Warnings and Precautions (5.10) ]. Advise patients to notify their healthcare provider if they are using a continuous glucose monitoring system while taking hydroxyurea capsules [see Warnings and Precautions (5.11) ]. Rx only Manufactured by: Halo Pharmaceutical Inc 30 North Jefferson Road, Whippany, NJ 07981 Distributed by: Leading Pharma, LLC Fairfield, NJ 07004 Rev.06 11/23 Marketed by: GSMS, Inc. Camarillo, CA 93012 USA"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Individualize treatment based on tumor type, disease state, response to treatment, patient risk factors, and current clinical practice standards. (2.1) Renal impairment: Reduce the dose of hydroxyurea by 50% in patients with creatinine clearance less than 60 mL/min. ( 2.3 , 8.6, 12.3 ) 2.1 Dosing Information Hydroxyurea is used alone or in conjunction with other antitumor agents or radiation therapy to treat neoplastic diseases. Individualize treatment based on tumor type, disease state, response to treatment, patient risk factors, and current clinical practice standards. Base all dosage on the patient’s actual or ideal weight, whichever is less. Hydroxyurea is a cytotoxic drug. Follow applicable special handling and disposal procedures [ see References (15) ]. Swallow hydroxyurea capsule whole. Do NOT open, break, or chew capsules because hydroxyurea is a cytotoxic drug. Prophylactic administration of folic acid is recommended [ see Warnings and Precautions (5.8) ]. Monitor blood counts at least once a week during hydroxyurea therapy. Severe anemia must be corrected before initiating therapy with hydroxyurea. 2.2 Dose Modifications for Toxicity Monitor for the following and reduce the dose or discontinue hydroxyurea accordingly: Myelosuppression [see Warnings and Precautions (5.1) ] Cutaneous vasculitis [see Warnings and Precautions (5.5) ] 2.3 Dose Modifications for Renal Impairment Reduce the dose of hydroxyurea capsules by 50% in patients with measured creatinine clearance of less than 60 mL/min or with end-stage renal disease (ESRD) [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3) ]. Creatinine Clearance (mL/min) Recommended Hydroxyurea Capsules Initial Dose (mg/kg once daily) ≥60 15 <60 or ESRD On dialysis days, administer hydroxyurea capsules to patients following hemodialysis. 7.5 Close monitoring of hematologic parameters is advised in these patients.","2.1 Dosing Information Hydroxyurea is used alone or in conjunction with other antitumor agents or radiation therapy to treat neoplastic diseases. Individualize treatment based on tumor type, disease state, response to treatment, patient risk factors, and current clinical practice standards. Base all dosage on the patient’s actual or ideal weight, whichever is less. Hydroxyurea is a cytotoxic drug. Follow applicable special handling and disposal procedures [ see References (15) ]. Swallow hydroxyurea capsule whole. Do NOT open, break, or chew capsules because hydroxyurea is a cytotoxic drug. Prophylactic administration of folic acid is recommended [ see Warnings and Precautions (5.8) ]. Monitor blood counts at least once a week during hydroxyurea therapy. Severe anemia must be corrected before initiating therapy with hydroxyurea.","2.2 Dose Modifications for Toxicity Monitor for the following and reduce the dose or discontinue hydroxyurea accordingly: Myelosuppression [see Warnings and Precautions (5.1) ] Cutaneous vasculitis [see Warnings and Precautions (5.5) ]","2.3 Dose Modifications for Renal Impairment Reduce the dose of hydroxyurea capsules by 50% in patients with measured creatinine clearance of less than 60 mL/min or with end-stage renal disease (ESRD) [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3) ]. Creatinine Clearance (mL/min) Recommended Hydroxyurea Capsules Initial Dose (mg/kg once daily) ≥60 15 <60 or ESRD On dialysis days, administer hydroxyurea capsules to patients following hemodialysis. 7.5 Close monitoring of hematologic parameters is advised in these patients."],"spl_product_data_elements":["HYDROXYUREA HYDROXYUREA D&C YELLOW NO. 10 FD&C RED NO. 3 FD&C BLUE NO. 1 GELATIN ANHYDROUS LACTOSE MAGNESIUM STEARATE SILICON DIOXIDE TITANIUM DIOXIDE HYDROXYUREA HYDROXYUREA cap-opaque green body-opaque light pink LP;164"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Capsules: 500 mg, green opaque cap imprinted in black with “LP 164” and light pink opaque body imprinted in black with “LP 164” • Capsules: 500 mg"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Lactation: Advise women not to breastfeed. (8.2) Geriatric Use: Care should be taken in dose selection and may require a lower dose regimen and monitoring of renal function. (8.5) 8.1 Pregnancy Risk Summary Hydroxyurea capsules can cause fetal harm based on findings from animal studies and the drug’s mechanism of action [see Clinical Pharmacology (12.1) ]. There are no data with hydroxyurea capsules use in pregnant women to inform a drug-associated risk. In animal reproduction studies, administration of hydroxyurea to pregnant rats and rabbits during organogenesis produced embryotoxic and teratogenic effects at doses 0.8 times and 0.3 times, respectively, the maximum recommended human daily dose on a mg/m 2 basis (see Data). Advise women of the potential risk to a fetus and to avoid becoming pregnant while being treated with hydroxyurea capsules. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%–4% and 15%–20%, respectively. Data Animal Data Hydroxyurea has been demonstrated to be a potent teratogen in a wide variety of animal models, including mice, hamsters, cats, miniature swine, dogs, and monkeys at doses within 1-fold of the human dose given on a mg/m 2 basis. Hydroxyurea is embryotoxic and causes fetal malformations (partially ossified cranial bones, absence of eye sockets, hydrocephaly, bipartite sternebrae, missing lumbar vertebrae) at 180 mg/kg/day (about 0.8 times the maximum recommended human daily dose on a mg/m 2 basis) in rats and at 30 mg/kg/day (about 0.3 times the maximum recommended human daily dose on a mg/m 2 basis) in rabbits. Embryotoxicity was characterized by decreased fetal viability, reduced live litter sizes, and developmental delays. Hydroxyurea crosses the placenta. Single doses of ≥375 mg/kg (about 1.7 times the maximum recommended human daily dose on a mg/m 2 basis) to rats caused growth retardation and impaired learning ability. 8.2 Lactation Risk Summary Hydroxyurea is excreted in human milk. Because of the potential for serious adverse reactions in a breastfed infant from hydroxyurea, including carcinogenicity, discontinue breastfeeding during treatment with hydroxyurea capsules. 8.3 Females and Males of Reproductive Potential Pregnancy Testing Verify the pregnancy status of females of reproductive potential prior to initiating hydroxyurea therapy. Contraception Females Hydroxyurea capsules can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1) ]. Advise females of reproductive potential to use effective contraception during and after treatment with hydroxyurea capsules for at least 6 months after therapy. Advise females to immediately report pregnancy. Males Hydroxyurea may damage spermatozoa and testicular tissue, resulting in possible genetic abnormalities. Males with female sexual partners of reproductive potential should use effective contraception during and after treatment with hydroxyurea capsules for at least 1 year after therapy [see Nonclinical Toxicology (13.1) ]. Infertility Males Based on findings in animals and humans, male fertility may be compromised by treatment with hydroxyurea capsules. Azoospermia or oligospermia, sometimes reversible, has been observed in men. Inform male patients about the possibility of sperm conservation before the start of therapy [see Adverse Reactions (6) and Nonclinical Toxicology (13.1) ]. 8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established. 8.5 Geriatric Use Elderly patients may be more sensitive to the effects of hydroxyurea and may require a lower dose regimen. Hydroxyurea is excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function [see Dosage and Administration (2.3) ]. 8.6 Renal Impairment The exposure to hydroxyurea is higher in patients with creatinine clearance of less than 60 mL/min or in patients with end-stage renal disease (ESRD). Reduce dosage and closely monitor the hematologic parameters when hydroxyurea capsules is to be administered to these patients [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3) ]. 8.7 Hepatic Impairment There are no data that support specific guidance for dosage adjustment in patients with hepatic impairment. Close monitoring of hematologic parameters is advised in these patients.","8.1 Pregnancy Risk Summary Hydroxyurea capsules can cause fetal harm based on findings from animal studies and the drug’s mechanism of action [see Clinical Pharmacology (12.1) ]. There are no data with hydroxyurea capsules use in pregnant women to inform a drug-associated risk. In animal reproduction studies, administration of hydroxyurea to pregnant rats and rabbits during organogenesis produced embryotoxic and teratogenic effects at doses 0.8 times and 0.3 times, respectively, the maximum recommended human daily dose on a mg/m 2 basis (see Data). Advise women of the potential risk to a fetus and to avoid becoming pregnant while being treated with hydroxyurea capsules. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%–4% and 15%–20%, respectively. Data Animal Data Hydroxyurea has been demonstrated to be a potent teratogen in a wide variety of animal models, including mice, hamsters, cats, miniature swine, dogs, and monkeys at doses within 1-fold of the human dose given on a mg/m 2 basis. Hydroxyurea is embryotoxic and causes fetal malformations (partially ossified cranial bones, absence of eye sockets, hydrocephaly, bipartite sternebrae, missing lumbar vertebrae) at 180 mg/kg/day (about 0.8 times the maximum recommended human daily dose on a mg/m 2 basis) in rats and at 30 mg/kg/day (about 0.3 times the maximum recommended human daily dose on a mg/m 2 basis) in rabbits. Embryotoxicity was characterized by decreased fetal viability, reduced live litter sizes, and developmental delays. Hydroxyurea crosses the placenta. Single doses of ≥375 mg/kg (about 1.7 times the maximum recommended human daily dose on a mg/m 2 basis) to rats caused growth retardation and impaired learning ability.","8.2 Lactation Risk Summary Hydroxyurea is excreted in human milk. Because of the potential for serious adverse reactions in a breastfed infant from hydroxyurea, including carcinogenicity, discontinue breastfeeding during treatment with hydroxyurea capsules.","8.3 Females and Males of Reproductive Potential Pregnancy Testing Verify the pregnancy status of females of reproductive potential prior to initiating hydroxyurea therapy. Contraception Females Hydroxyurea capsules can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1) ]. Advise females of reproductive potential to use effective contraception during and after treatment with hydroxyurea capsules for at least 6 months after therapy. Advise females to immediately report pregnancy. Males Hydroxyurea may damage spermatozoa and testicular tissue, resulting in possible genetic abnormalities. Males with female sexual partners of reproductive potential should use effective contraception during and after treatment with hydroxyurea capsules for at least 1 year after therapy [see Nonclinical Toxicology (13.1) ]. Infertility Males Based on findings in animals and humans, male fertility may be compromised by treatment with hydroxyurea capsules. Azoospermia or oligospermia, sometimes reversible, has been observed in men. Inform male patients about the possibility of sperm conservation before the start of therapy [see Adverse Reactions (6) and Nonclinical Toxicology (13.1) ].","8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established.","8.5 Geriatric Use Elderly patients may be more sensitive to the effects of hydroxyurea and may require a lower dose regimen. Hydroxyurea is excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function [see Dosage and Administration (2.3) ].","8.6 Renal Impairment The exposure to hydroxyurea is higher in patients with creatinine clearance of less than 60 mL/min or in patients with end-stage renal disease (ESRD). Reduce dosage and closely monitor the hematologic parameters when hydroxyurea capsules is to be administered to these patients [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3) ].","8.7 Hepatic Impairment There are no data that support specific guidance for dosage adjustment in patients with hepatic impairment. Close monitoring of hematologic parameters is advised in these patients."],"dosage_and_administration_table":["<table cellspacing=\"0\" cellpadding=\"0\" styleCode=\"Footnote\"><tbody><tr><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Creatinine Clearance (mL/min)</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Recommended Hydroxyurea Capsules Initial Dose</content></paragraph><paragraph><content styleCode=\"bold\">(mg/kg once daily)</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>&#x2265;60</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>15</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Lrule Toprule\"><paragraph>&lt;60 or ESRD <footnote ID=\"L4e9cc8ff-7600-4485-8adc-da7674371b32\">On dialysis days, administer hydroxyurea capsules to patients following hemodialysis.</footnote></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>7.5</paragraph></td></tr></tbody></table>","<table cellspacing=\"0\" cellpadding=\"0\" styleCode=\"Footnote\"><tbody><tr><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Creatinine Clearance (mL/min)</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Recommended Hydroxyurea Capsules Initial Dose</content></paragraph><paragraph><content styleCode=\"bold\">(mg/kg once daily)</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>&#x2265;60</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>15</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Lrule Toprule\"><paragraph>&lt;60 or ESRD <footnote ID=\"L4e9cc8ff-7600-4485-8adc-da7674371b32\">On dialysis days, administer hydroxyurea capsules to patients following hemodialysis.</footnote></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>7.5</paragraph></td></tr></tbody></table>"],"package_label_principal_display_panel":["Hydroxyurea capsules, USP container label 51407-909-01LB - Hydroxyurea 500 mg - Rev. 0624.jpg"]},"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"2068 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"1490 reports"},{"date":"","signal":"SICKLE CELL ANAEMIA WITH CRISIS","source":"FDA FAERS","actionTaken":"1475 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"1378 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"1279 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"1045 reports"},{"date":"","signal":"ANAEMIA","source":"FDA FAERS","actionTaken":"1020 reports"},{"date":"","signal":"DEATH","source":"FDA FAERS","actionTaken":"1003 reports"},{"date":"","signal":"HAEMOGLOBIN DECREASED","source":"FDA FAERS","actionTaken":"930 reports"},{"date":"","signal":"PYREXIA","source":"FDA FAERS","actionTaken":"906 reports"}],"drugInteractions":[{"drug":"Antiretroviral drugs","action":"Monitor for signs and symptoms of pancreatitis and hepatotoxicity. Avoid combination with didanosine and stavudine.","effect":"Increased toxicity, including pancreatitis, hepatotoxicity, and peripheral neuropathy."},{"drug":"Uric acid, urea, or lactic acid assays","action":"Use alternative methods for these assays.","effect":"Analytical interference leading to falsely elevated results."},{"drug":"Continuous glucose monitoring systems","action":"Consult with healthcare provider before prescribing hydroxyurea to patients using CGM systems.","effect":"Falsely elevated sensor glucose results, potentially leading to hypoglycemia."}],"commonSideEffects":[{"effect":"Anemia","drugRate":"≥30%","severity":"serious","_validated":true},{"effect":"Leukopenia","drugRate":"≥30%","severity":"serious","_validated":true},{"effect":"Thrombocytopenia","drugRate":"≥30%","severity":"serious","_validated":true},{"effect":"Nausea","drugRate":"≥30%","severity":"moderate","_validated":true},{"effect":"Vomiting","drugRate":"≥30%","severity":"moderate","_validated":true},{"effect":"Diarrhea","drugRate":"≥30%","severity":"moderate","_validated":true},{"effect":"Constipation","drugRate":"≥30%","severity":"moderate","_validated":true},{"effect":"Stomatitis","drugRate":"≥30%","severity":"moderate","_validated":true},{"effect":"Anorexia","drugRate":"≥30%","severity":"moderate","_validated":true},{"effect":"Fever","drugRate":"≥30%","severity":"moderate","_validated":true},{"effect":"Chills","drugRate":"≥30%","severity":"moderate","_validated":true},{"effect":"Malaise","drugRate":"≥30%","severity":"moderate","_validated":true},{"effect":"Edema","drugRate":"≥30%","severity":"moderate","_validated":true},{"effect":"Asthenia","drugRate":"≥30%","severity":"moderate","_validated":true}],"contraindications":["In patients who have demonstrated a previous hypersensitivity to hydroxyurea or any other component of the formulation."],"specialPopulations":{"Pregnancy":"Hydroxyurea can cause fetal harm based on findings from animal studies. Advise women to avoid becoming pregnant while being treated with hydroxyurea.","Geriatric use":"Elderly patients may be more sensitive to the effects of hydroxyurea and may require a lower dose regimen. Care should be taken in dose selection, and it may be useful to monitor renal function.","Paediatric use":"Safety and effectiveness in pediatric patients have not been established.","Renal impairment":"Reduce the dose of hydroxyurea by 50% in patients with creatinine clearance less than 60 mL/min or with end-stage renal disease (ESRD).","Hepatic impairment":"There are no data that support specific guidance for dosage adjustment in patients with hepatic impairment. Close monitoring of hematologic parameters is advised."},"seriousAdverseEvents":[{"event":"Myelosuppression","detail":"Severe anemia, leukopenia, and thrombocytopenia can occur.","severity":"serious","incidence":"Not specified"},{"event":"Hemolytic anemia","detail":"Can occur, especially in patients with pre-existing anemia.","severity":"serious","incidence":"Not specified"},{"event":"Malignancies","detail":"Secondary malignancies have been reported.","severity":"serious","incidence":"Not specified"},{"event":"Vasculitic toxicities","detail":"Cutaneous vasculitis and other vasculitic reactions can occur.","severity":"serious","incidence":"Not specified"},{"event":"Radiation recall","detail":"Can occur when hydroxyurea is used in combination with radiation therapy.","severity":"serious","incidence":"Not specified"},{"event":"Macrocytosis","detail":"Can occur and may be a sign of bone marrow toxicity.","severity":"moderate","incidence":"Not specified"},{"event":"Pulmonary toxicity","detail":"Diffuse pulmonary infiltrates, dyspnea, and pulmonary fibrosis have been reported.","severity":"serious","incidence":"Not specified"},{"event":"Systemic lupus erythematosus","detail":"Has been reported in postmarketing experience.","severity":"serious","incidence":"Not specified"},{"event":"Drug-induced fever","detail":"Fever requiring hospitalization has been reported, often within 6 weeks of initiation.","severity":"serious","incidence":"Not specified"}]},"trials":[],"_chembl":null,"aliases":["hydroxycarbamide"],"patents":[{"type":"Formulation","number":"12409156","applicant":"NOVA LABORATORIES LTD","territory":"US","tradeName":"XROMI","expiryDate":"2041-12-23"}],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$0.2232/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$81","description":"HYDROXYUREA 500 MG CAPSULE","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=HYDROXYUREA","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:33:45.023633+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T01:33:45.023557+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:33:50.367022+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T01:33:44.138254+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=HYDROXYUREA","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:33:50.694594+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:33:38.233356+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:33:38.233386+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:33:38.233392+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T01:33:52.474953+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Ribonucleoside-diphosphate reductase RR1 inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:33:51.893701+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL467/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:33:51.542945+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA213438","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:33:38.233394+00:00"}},"allNames":"HYDROXYUREA, hydroxycarbamide, hydroxyurea","offLabel":[],"timeline":[{"date":"","type":"neutral","milestone":"Discovery/IND filing","regulator":"none","description":"Initial discovery and IND filing for hydroxyurea."},{"date":"","type":"neutral","milestone":"Phase 1 initiation","regulator":"none","description":"Initiation of Phase 1 clinical trials."},{"date":"","type":"neutral","milestone":"Phase 2 initiation","regulator":"none","description":"Initiation of Phase 2 clinical trials."},{"date":"","type":"neutral","milestone":"Phase 3 initiation","regulator":"none","description":"Initiation of Phase 3 clinical trials."},{"date":"","type":"positive","milestone":"FDA approval for resistant chronic myeloid leukemia","regulator":"FDA","description":"FDA approval for the treatment of resistant chronic myeloid leukemia."},{"date":"","type":"positive","milestone":"FDA approval for locally advanced squamous cell carcinomas of the head and neck","regulator":"FDA","description":"FDA approval for the treatment of locally advanced squamous cell carcinomas of the head and neck in combination with concurrent chemoradiation."},{"date":"","type":"neutral","milestone":"Off-label use in sickle cell disease","regulator":"none","description":"Widespread off-label use in sickle cell disease for reducing vaso-occlusive crises."},{"date":"","type":"neutral","milestone":"Phase 3 trial initiation for polycythemia vera","regulator":"none","description":"Initiation of Phase 3 clinical trials for polycythemia vera."},{"date":"","type":"neutral","milestone":"Phase 3 trial initiation for essential thrombocythemia","regulator":"none","description":"Initiation of Phase 3 clinical trials for essential thrombocythemia."},{"date":"","type":"neutral","milestone":"Phase 3 trial initiation for sickle cell disease","regulator":"none","description":"Initiation of Phase 3 clinical trials for sickle cell disease."},{"date":"","type":"negative","milestone":"Generic competition begins","regulator":"none","description":"Entry of generic hydroxyurea into the market."}],"_dailymed":{"setId":"c84a2241-6c05-480f-8a5b-049e08c27d73","title":"HYDROXYUREA CAPSULE [AMERICAN HEALTH PACKAGING]"},"ecosystem":[],"mechanism":{"target":"Ribonucleotide reductase","novelty":"me-too","modality":"small molecule","drugClass":"Antimetabolite [EPC]","explanation":"","oneSentence":"","technicalDetail":"Hydroxyurea selectively targets ribonucleotide reductase, a key enzyme in DNA synthesis. It binds to the active site of the enzyme, preventing the conversion of ribonucleotides to deoxyribonucleotides. This inhibition leads to a depletion of deoxyribonucleotide pools, halting DNA replication and cell division. Hydroxyurea has a relatively short half-life and is primarily excreted via the kidneys."},"_scrapedAt":"2026-03-27T23:33:10.800Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"notes":"","yoyGrowth":"","launchDate":"","marketShare":"","revenueYear":"","annualCostUS":"","currentRevenue":"","percentOfCompany":"","patientPopulation":"","peakSalesEstimate":"","genericCompetition":"yes"},"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:33:56.108818+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"name":"Imatinib","slug":"imatinib","company":"Novartis","advantage":"First-line treatment for chronic myeloid leukemia with better efficacy and fewer side effects."},{"name":"Dasatinib","slug":"dasatinib","company":"Bristol Myers Squibb","advantage":"Second-generation TKI with improved efficacy in imatinib-resistant CML."},{"name":"Nilotinib","slug":"nilotinib","company":"Novartis","advantage":"Second-generation TKI with improved efficacy and fewer side effects compared to imatinib."},{"name":"Crizanlizumab","slug":"crizanlizumab","company":"Novartis","advantage":"Monoclonal antibody for reducing vaso-occlusive crises in sickle cell disease."},{"name":"Pacritinib","slug":"pacritinib","company":"Swedish Orphan Biovitrum","advantage":"JAK2 inhibitor for treating myelofibrosis with fewer side effects."}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"line":"1L","name":"Resistant chronic myeloid leukemia","notes":"","regulator":"FDA","approvalDate":""},{"line":"1L","name":"Locally advanced squamous cell carcinomas of the head and neck (excluding lip) in combination with concurrent chemoradiation","notes":"","regulator":"FDA","approvalDate":""}],"offLabel":[{"name":"Sickle cell disease","notes":"Widely used off-label for reducing vaso-occlusive crises and improving quality of life.","evidenceLevel":"strong"}],"pipeline":[{"name":"Polycythemia vera","notes":"","phase":"Phase 3","status":"recruiting"},{"name":"Essential thrombocythemia","notes":"","phase":"Phase 3","status":"recruiting"},{"name":"Sickle cell disease","notes":"","phase":"Phase 3","status":"recruiting"}]},"labelChanges":[],"relatedDrugs":[{"name":"Azathioprine","slug":"azathioprine","company":"American Health Packaging","genericName":"AZATHIOPRINE","relationship":"same-class"},{"name":"Cladribine","slug":"cladribine","company":"Apotex Corp.","genericName":"CLADRIBINE","relationship":"same-class"},{"name":"Floxuridine","slug":"floxuridine","company":"JND Therapeutics, Inc.","genericName":"FLOXURIDINE","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06456346","phase":"PHASE3","title":"Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-07-16","conditions":"Essential Thrombocythemia","enrollment":300},{"nctId":"NCT06439082","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-10-24","conditions":"Sickle Cell Disease","enrollment":315},{"nctId":"NCT00920972","phase":"PHASE1, PHASE2","title":"Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2001-12","conditions":"Metabolic Disorders, Hematologic, Immune, or Bone Marrow Disorders, Hemoglobinopathies","enrollment":220},{"nctId":"NCT06093672","phase":"PHASE3","title":"Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera","status":"RECRUITING","sponsor":"Italfarmaco","startDate":"2024-03-26","conditions":"Polycythemia Vera","enrollment":220},{"nctId":"NCT06871410","phase":"PHASE1","title":"Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-03-02","conditions":"Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":26},{"nctId":"NCT06955169","phase":"PHASE2","title":"Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment","status":"RECRUITING","sponsor":"RTOG Foundation, Inc.","startDate":"2025-12-24","conditions":"Intracranial Meningioma","enrollment":153},{"nctId":"NCT07488520","phase":"PHASE4","title":"Integrating Point of Care Testing (POCT) For Newborn Screening and Early Care for Sickle Cell Disease in Yopougon, Côte d'Ivoire","status":"NOT_YET_RECRUITING","sponsor":"Swiss Tropical & Public Health Institute","startDate":"2026-04","conditions":"Sickle Cell Disease (SCD)","enrollment":120},{"nctId":"NCT06079879","phase":"PHASE3","title":"A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-31","conditions":"Essential Thrombocythemia","enrollment":340},{"nctId":"NCT06930352","phase":"PHASE2","title":"Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy","status":"NOT_YET_RECRUITING","sponsor":"Uma Borate","startDate":"2026-04-10","conditions":"Acute Myeloid Leukemia","enrollment":70},{"nctId":"NCT05357482","phase":"PHASE1, PHASE2","title":"Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2022-05-12","conditions":"Sickle Cell Anemia, Beta Thalassemia","enrollment":40},{"nctId":"NCT05853458","phase":"PHASE4","title":"Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM Predictors","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-07-28","conditions":"Polycythemia Vera","enrollment":76},{"nctId":"NCT06063317","phase":"PHASE1","title":"A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS)","status":"TERMINATED","sponsor":"Imugene Limited","startDate":"2023-10-02","conditions":"Solid Tumor, Adult","enrollment":25},{"nctId":"NCT06526117","phase":"PHASE4","title":"Stroke Prevention in Nigeria 2 Trial","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2024-08-05","conditions":"Sickle Cell Disease, Stroke","enrollment":220},{"nctId":"NCT06923111","phase":"","title":"PASS of Xromi Comparing Safety and Effectiveness in Children Under 2 Years With Sickle Cell Disease [PRECISE PASS]","status":"RECRUITING","sponsor":"Nova Laboratories Limited","startDate":"2025-06-09","conditions":"Sickle Cell Disease","enrollment":180},{"nctId":"NCT07033598","phase":"PHASE2","title":"Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Theradex","startDate":"2026-01-01","conditions":"Leukemia, Myelomonocytic, Chronic","enrollment":66},{"nctId":"NCT05526924","phase":"PHASE1","title":"Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2023-03-07","conditions":"Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Carcinoma","enrollment":30},{"nctId":"NCT07232290","phase":"PHASE2","title":"Phase IIa Study on Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera","status":"RECRUITING","sponsor":"Chengdu Zenitar Biomedical Technology Co., Ltd","startDate":"2025-09-23","conditions":"Polycythemia Vera (PV)","enrollment":60},{"nctId":"NCT03165734","phase":"PHASE3","title":"A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis","status":"RECRUITING","sponsor":"Swedish Orphan Biovitrum","startDate":"2017-06-26","conditions":"Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis","enrollment":399},{"nctId":"NCT03974217","phase":"PHASE1","title":"Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2019-08-01","conditions":"Leukemia","enrollment":13},{"nctId":"NCT06979492","phase":"PHASE4","title":"Prophylactic Transfusion In Pregnant in Women With Sickle Cell Disease","status":"RECRUITING","sponsor":"Emory University","startDate":"2026-04","conditions":"Sickle Cell Disease, Pregnancy Related","enrollment":50},{"nctId":"NCT03511118","phase":"","title":"Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants","status":"RECRUITING","sponsor":"Duke University","startDate":"2018-10-04","conditions":"Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI","enrollment":1600},{"nctId":"NCT03708731","phase":"","title":"Exploring Adherence Monitoring in Sickle Cell Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2019-03-12","conditions":"Sickle Cell Disease","enrollment":36},{"nctId":"NCT07116772","phase":"","title":"Serial Assessment of Fertility Experiences","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2023-07-10","conditions":"Sickle Cell Anemia","enrollment":250},{"nctId":"NCT03814746","phase":"PHASE3","title":"Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2019-07-26","conditions":"Sickle Cell Disease (SCD)","enrollment":255},{"nctId":"NCT06786234","phase":"PHASE1","title":"A Phase 1 Study to Assess STP938 as a Monotherapy in Adults With High Risk Essential Thrombocythaemia","status":"RECRUITING","sponsor":"Step Pharma, SAS","startDate":"2025-06-18","conditions":"Essential Thrombocythaemia","enrollment":20},{"nctId":"NCT04217356","phase":"","title":"Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2020-08-05","conditions":"Myelofibrosis, High-Risk Cancer, Bone Marrow Cancer","enrollment":90},{"nctId":"NCT03500731","phase":"PHASE1, PHASE2","title":"Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure","status":"RECRUITING","sponsor":"Paul Szabolcs","startDate":"2018-04-19","conditions":"Idiopathic Pulmonary Fibrosis, Emphysema or COPD","enrollment":8},{"nctId":"NCT04528355","phase":"","title":"Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC","status":"RECRUITING","sponsor":"Paul Szabolcs","startDate":"2020-08-20","conditions":"Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD)","enrollment":50},{"nctId":"NCT05451940","phase":"PHASE1, PHASE2","title":"Hydroxyurea and EPO in Sickle Cell Disease","status":"COMPLETED","sponsor":"Julia Xu","startDate":"2023-05-25","conditions":"Anemia, Sickle Cell, Sickle Cell Disease","enrollment":17},{"nctId":"NCT03128996","phase":"PHASE1, PHASE2","title":"Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2017-03-20","conditions":"Severe Sickle Cell Disease, Bone Marrow Failure Syndromes, Metabolic Disorders","enrollment":29},{"nctId":"NCT05405114","phase":"PHASE2","title":"Research Study Investigating How Well NDec Works in People With Sickle Cell Disease","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2022-07-07","conditions":"Sickle Cell Disease","enrollment":96},{"nctId":"NCT07292259","phase":"PHASE2","title":"Combination of Thalidomide and Hydroxyuria in Transfusion Dependent Thalasemmia","status":"RECRUITING","sponsor":"Pakistan Blood and Marrow Transplant (PBMT) Group","startDate":"2024-01-01","conditions":"Transfusion Dependent Beta Thalassemia","enrollment":150},{"nctId":"NCT05020652","phase":"PHASE2","title":"A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2021-11-11","conditions":"Moderate and High Risk Myelofibrosis","enrollment":107},{"nctId":"NCT03013998","phase":"PHASE1, PHASE2","title":"Study of Biomarker-Based Treatment of Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Beat AML, LLC","startDate":"2016-11","conditions":"Previously Untreated Relapsed Refractory Acute Myeloid Leukemia","enrollment":3000},{"nctId":"NCT01962415","phase":"PHASE2","title":"Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT","status":"RECRUITING","sponsor":"Paul Szabolcs","startDate":"2014-02-04","conditions":"Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD)","enrollment":100},{"nctId":"NCT04576156","phase":"PHASE3","title":"A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Geron Corporation","startDate":"2021-04-12","conditions":"Myelofibrosis","enrollment":327},{"nctId":"NCT05398809","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-01-18","conditions":"Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced), Alopecia Areata","enrollment":70},{"nctId":"NCT06552429","phase":"PHASE2","title":"Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ET","status":"RECRUITING","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2024-08-29","conditions":"Essential Thrombocythemia","enrollment":27},{"nctId":"NCT05213572","phase":"","title":"Observational Study to Deeply Phenotype Major Organs in Sickle Cell Disease After Curative Therapies","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2022-03-24","conditions":"Mortality in Sickle Cell, Sickle Cell Cardiopulmonary Complications, Sickle Cell Organ Damage","enrollment":200},{"nctId":"NCT00726232","phase":"PHASE2","title":"Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2008-08-20","conditions":"Myeloproliferative Neoplasm (MPN)","enrollment":73},{"nctId":"NCT03474965","phase":"PHASE2","title":"Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-10-01","conditions":"Sickle Cell Disease (SCD)","enrollment":117},{"nctId":"NCT02158858","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies","status":"COMPLETED","sponsor":"Constellation Pharmaceuticals","startDate":"2014-07-16","conditions":"Myelofibrosis, Leukemia, Myelocytic, Acute, Myelodysplastic/Myeloproliferative Neoplasm","enrollment":336},{"nctId":"NCT07210450","phase":"PHASE2, PHASE3","title":"Effect of L-Glutamine on Pulmonary Artery Pressure in Patients With Non-Transfusion-Dependent Thalassemia","status":"COMPLETED","sponsor":"Mazandaran University of Medical Sciences","startDate":"2023-08-15","conditions":"Pulmonary Artery Pressure, Thalassemia, Non-transfusion Dependent Thalassemia","enrollment":8},{"nctId":"NCT04562870","phase":"PHASE2","title":"A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Karyopharm Therapeutics Inc","startDate":"2021-03-17","conditions":"Myelofibrosis","enrollment":112},{"nctId":"NCT05249452","phase":"","title":"Adding Azathioprine/Hydroxyurea Preconditioning to Alemtuzumab/TBI to Reduce Risk of Graft Failure in MSD HSCT in Adult SCD Patients","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2018-03-08","conditions":"Sickle Cell Disease","enrollment":20},{"nctId":"NCT04229979","phase":"PHASE3","title":"Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sellas Life Sciences Group","startDate":"2021-02-08","conditions":"Acute Myeloid Leukemia","enrollment":127},{"nctId":"NCT07170592","phase":"PHASE1","title":"A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients","status":"NOT_YET_RECRUITING","sponsor":"Bionoxx Inc.","startDate":"2025-12","conditions":"Treatment-Refractory Solid Tumors","enrollment":24},{"nctId":"NCT04662931","phase":"PHASE4","title":"An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-07-14","conditions":"Sickle Cell Disease (SCD)","enrollment":140},{"nctId":"NCT07190833","phase":"PHASE1","title":"A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)","status":"NOT_YET_RECRUITING","sponsor":"Bionoxx Inc.","startDate":"2025-11","conditions":"Treatment-Refractory Solid Tumors","enrollment":27},{"nctId":"NCT05953584","phase":"PHASE2","title":"A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke","status":"RECRUITING","sponsor":"Forma Therapeutics, Inc.","startDate":"2023-06-20","conditions":"Sickle Cell Disease","enrollment":27},{"nctId":"NCT06578507","phase":"PHASE2","title":"Pharmacokinetics, Efficacy and Safety of Twice Daily Dosing Regimen of Hydroxycarbamide Dispersible Tablets in Children With Sickle Cell Disease","status":"RECRUITING","sponsor":"Theravia","startDate":"2025-01-21","conditions":"Sickle Cell Disease","enrollment":50},{"nctId":"NCT07177300","phase":"PHASE4","title":"Effectiveness of Nontraditional Hydroxyurea Algorithms: Novel and Clinical Evaluations (ENHANCE)","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2024-12-19","conditions":"Sickle Cell Anemia (HbSS), Sickle-β0-thalassemia (HbSβ0)","enrollment":50},{"nctId":"NCT06326190","phase":"PHASE2","title":"177Lu-DOTATATE for Recurrent Meningioma","status":"RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2025-03-10","conditions":"Recurrent Meningioma","enrollment":136},{"nctId":"NCT03860844","phase":"PHASE2","title":"Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Sanofi","startDate":"2019-08-06","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":67},{"nctId":"NCT04808778","phase":"","title":"Stroke Prevention in Young Adults With Sickle Cell Anemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2021-05-17","conditions":"Sickle Cell Disease, Sickle Cell Anemia, Stroke, Ischemic","enrollment":250},{"nctId":"NCT05548062","phase":"","title":"Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia Vera","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-03-02","conditions":"Polycythemia Vera","enrollment":242},{"nctId":"NCT02769845","phase":"NA","title":"SACRED A Prospective Research Study to Reduce Stroke in Children With Sickle Cell Anemia","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2016-03-16","conditions":"Sickle Cell Anemia","enrollment":283},{"nctId":"NCT02556099","phase":"PHASE2","title":"EXTEND EXpanding Treatment for Existing Neurological Disease","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2014-08","conditions":"Sickle Cell Anemia","enrollment":43},{"nctId":"NCT04362293","phase":"PHASE2","title":"Reduced Intensity Transplantation for Severe Sickle Cell Disease","status":"SUSPENDED","sponsor":"St. Jude Children's Research Hospital","startDate":"2020-04-30","conditions":"Sickle Cell Disease","enrollment":40},{"nctId":"NCT04285086","phase":"PHASE3","title":"Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance","status":"ACTIVE_NOT_RECRUITING","sponsor":"PharmaEssentia","startDate":"2020-08-25","conditions":"Essential Thrombocythemia","enrollment":174},{"nctId":"NCT03653338","phase":"PHASE1, PHASE2","title":"T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias","status":"RECRUITING","sponsor":"Paul Szabolcs","startDate":"2018-08-02","conditions":"Sickle Cell Anemia, Beta-thalassemia Major, Diamond-blackfan Anemia","enrollment":5},{"nctId":"NCT01461837","phase":"PHASE2","title":"Haplo T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"New York Medical College","startDate":"2012-01","conditions":"Sickle Cell Disease","enrollment":21},{"nctId":"NCT05485948","phase":"PHASE2","title":"A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU","status":"ACTIVE_NOT_RECRUITING","sponsor":"PharmaEssentia","startDate":"2021-10-08","conditions":"Polycythemia Vera","enrollment":49},{"nctId":"NCT04093986","phase":"","title":"Hydroxyurea Exposure Limiting Pregnancy and Follow-Up Lactation","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2019-12-22","conditions":"Sickle Cell Disease, Sickle Cell Anemia","enrollment":200},{"nctId":"NCT03948867","phase":"PHASE2","title":"Stroke Prevention With Hydroxyurea Enabled Through Research and Education (SPHERE)","status":"ENROLLING_BY_INVITATION","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2019-04-24","conditions":"Sickle Cell Anemia in Children","enrollment":202},{"nctId":"NCT02286154","phase":"NA","title":"Therapeutic Response Evaluation and Adherence Trial (TREAT)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2014-10","conditions":"Anemia, Sickle Cell","enrollment":150},{"nctId":"NCT07066072","phase":"NA","title":"The Radiofrequency Therapy in Management of Sickle Cell Disease Chronic Pain RCT Tested the Effect of TECAR Therapy on Sickle Cell Disease Chronic Pain.","status":"COMPLETED","sponsor":"Cairo University","startDate":"2022-12-01","conditions":"the Use of Radiofrequency Ablation in Form of TECAR(Capacitive and Resistive Transfer Energy) in Chronic Pain of Sickle Cell Disease Patients","enrollment":170},{"nctId":"NCT06199557","phase":"PHASE1, PHASE2","title":"A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML/HR-MDS Patients","status":"RECRUITING","sponsor":"Haukeland University Hospital","startDate":"2024-05-23","conditions":"Acute Myeloid Leukemia, Adult, Myelodysplastic Syndromes, Adult","enrollment":48},{"nctId":"NCT03789591","phase":"PHASE3","title":"Hydroxyurea Optimization Through Precision Study","status":"COMPLETED","sponsor":"Lifespan","startDate":"2019-01-17","conditions":"Sickle Cell Disease, Sickle Cell Anemia","enrollment":104},{"nctId":"NCT03442114","phase":"NA","title":"Shared-Decision Making for Hydroxyurea","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2018-07-12","conditions":"Sickle Cell Anemia, Children, Only","enrollment":176},{"nctId":"NCT04687176","phase":"PHASE2","title":"Frontline Oral Arsenic Trioxide for APL","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2021-01-01","conditions":"Acute Promyelocytic Leukemia","enrollment":100},{"nctId":"NCT02577926","phase":"PHASE2","title":"The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"RWTH Aachen University","startDate":"2015-10","conditions":"Polycythemia Vera (PV), Essential Thrombocythemia (ET)","enrollment":207},{"nctId":"NCT06005324","phase":"PHASE1","title":"Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2023-12-18","conditions":"HPV-Negative Squamous Cell Carcinoma","enrollment":36},{"nctId":"NCT06490601","phase":"PHASE2","title":"Long Term Beta Thalassemia Treatment: Findings From The Extension Period","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Blood and Marrow Transplant (NIBMT), Pakistan","startDate":"2022-04-01","conditions":"Fetal Hemoglobin, Beta-Thalassemia, Hemoglobinopathies","enrollment":30},{"nctId":"NCT02577406","phase":"PHASE3","title":"An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation","status":"COMPLETED","sponsor":"Celgene","startDate":"2015-12-30","conditions":"Leukemia, Myeloid, Isocitrate Dehydrogenase","enrollment":319},{"nctId":"NCT06171217","phase":"PHASE2","title":"Realizing Effectiveness Across Continents With Hydroxyurea","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2023-10-27","conditions":"Sickle Cell Disease, Children","enrollment":810},{"nctId":"NCT03806452","phase":"PHASE2","title":"SIKAMIC (SIklos on Kidney Function and AlbuMInuria Clinical Trial)","status":"COMPLETED","sponsor":"Theravia","startDate":"2019-05-28","conditions":"Sickle Cell Disease","enrollment":86},{"nctId":"NCT01966731","phase":"PHASE1, PHASE2","title":"Realizing Effectiveness Across Continents With Hydroxyurea (REACH)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2014-06","conditions":"Sickle Cell Disease","enrollment":635},{"nctId":"NCT03944915","phase":"PHASE2","title":"De-Escalation Therapy for Human Papillomavirus Negative Disease","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2019-08-26","conditions":"Human Papilloma Virus, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck","enrollment":35},{"nctId":"NCT03107182","phase":"PHASE2","title":"Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2017-06-27","conditions":"HPV-Related Squamous Cell Carcinoma, HNSCC","enrollment":72},{"nctId":"NCT04329325","phase":"PHASE2","title":"Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-03-30","conditions":"Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Positive","enrollment":17},{"nctId":"NCT03263559","phase":"PHASE2","title":"Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2017-10-03","conditions":"Sickle Cell Disease","enrollment":95},{"nctId":"NCT04750707","phase":"PHASE3","title":"Hydroxyurea Therapy for Neurological and Cognitive Protection in Pediatric Sickle Cell Anemia in Uganda ( BRAINSAFE-II )","status":"COMPLETED","sponsor":"Global Health Uganda LTD","startDate":"2021-03-09","conditions":"Sickle Cell Anemia in Children","enrollment":270},{"nctId":"NCT01499888","phase":"PHASE1, PHASE2","title":"Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2011-11-11","conditions":"Sickle Cell Disease","enrollment":45},{"nctId":"NCT05285917","phase":"PHASE3","title":"Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa","status":"RECRUITING","sponsor":"Brown University","startDate":"2023-11-15","conditions":"Sickle Cell Anemia in Children, Sickle Cell Disease","enrollment":400},{"nctId":"NCT06264700","phase":"NA","title":"Applying Directly Observed Therapy to Hydroxyurea to Realize Effectiveness","status":"RECRUITING","sponsor":"Nationwide Children's Hospital","startDate":"2024-07-11","conditions":"Sickle Cell Disease","enrollment":60},{"nctId":"NCT06881056","phase":"NA","title":"Peginterferon α-2b Injection for Aerosol Therapy in Pediatric Respiratory Syncytial Virus Pneumonia","status":"RECRUITING","sponsor":"West China Second University Hospital","startDate":"2024-07-17","conditions":"Respiratory Syncytial Virus (RSV)","enrollment":90},{"nctId":"NCT01420783","phase":"PHASE2","title":"Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-10","conditions":"Hematopoietic Neoplasm","enrollment":81},{"nctId":"NCT04126681","phase":"PHASE2","title":"A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase","status":"COMPLETED","sponsor":"Ascentage Pharma Group Inc.","startDate":"2019-10-21","conditions":"Chronic Myeloid Leukemia, Chronic Phase","enrollment":144},{"nctId":"NCT04539678","phase":"","title":"SYTHROM Cohort, Myeloproliferative Neoplasia With Normal CBC and Thrombotic Complications","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2019-05-21","conditions":"Thrombotic Patients, Diagnosis of Myeloproliferative Neoplasia, Impact of Treatment With Cytoreducing Agent","enrollment":253},{"nctId":"NCT05662098","phase":"EARLY_PHASE1","title":"Alternative Dosing And Prevention of Transfusions (ADAPT)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2022-06-16","conditions":"Sickle Cell Disease","enrollment":100},{"nctId":"NCT06464458","phase":"NA","title":"Optimizing the Management of Sickle Cell Patients on Hydroxyurea: The Value of Therapeutic Pharmacological Monitoring","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2023-02-08","conditions":"Sickle Cell Disease","enrollment":30},{"nctId":"NCT06318143","phase":"NA","title":"mAnaging siCkle CELl disEase Through incReased AdopTion of hydroxyurEa in Nigeria","status":"RECRUITING","sponsor":"New York University","startDate":"2024-07-01","conditions":"Sickle Cell Disease","enrollment":900},{"nctId":"NCT06761560","phase":"PHASE2, PHASE3","title":"Optimizing Hydroxyurea Dosage With Pharmakokinetic in Patients Suffering of Moderate to Severe Sickle Cell Anemia","status":"NOT_YET_RECRUITING","sponsor":"Yves Pastore","startDate":"2025-01-15","conditions":"Sickle Cell Disease (SCD)","enrollment":29},{"nctId":"NCT04691323","phase":"NA","title":"The Longitudinal Relationship of HU Adherence to HRQOL, Barriers to Adherence and Habit in SCD.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2021-03-02","conditions":"Sickle Cell Disease, Sickle B+ Thalassemia, Sickle Beta Zero Thalassemia","enrollment":68},{"nctId":"NCT02165007","phase":"PHASE1","title":"Haploidentical Hematopoietic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Catherine Bollard","startDate":"2015-01","conditions":"Sickle Cell-thalassemia Disease, Thalassemia","enrollment":7},{"nctId":"NCT06606886","phase":"PHASE4","title":"Effects of Hydroxyurea and Metformin in Transfusion Dependent Beta-Thalassemia","status":"RECRUITING","sponsor":"Bahria University","startDate":"2024-09-16","conditions":"Transfusion Dependent Beta-thalassemia","enrollment":96},{"nctId":"NCT04688411","phase":"NA","title":"An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell Disease","status":"RECRUITING","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2020-09-28","conditions":"Sickle Cell Disease, Sickle Beta Zero Thalassemia, Sickle B+ Thalassemia","enrollment":40},{"nctId":"NCT04116502","phase":"PHASE3","title":"MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2019-10-25","conditions":"Polycythemia Vera","enrollment":586},{"nctId":"NCT03715972","phase":"","title":"Cerebrovascular Reserve and White Matter Disease in Patients with Chronic Anemia","status":"COMPLETED","sponsor":"Children's Hospital Los Angeles","startDate":"2018-07-15","conditions":"Thalassemia, Sickle Cell Disease, Healthy Controls","enrollment":165}],"_emaApprovals":[],"_faersSignals":[{"count":1626,"reaction":"OFF LABEL USE"},{"count":1250,"reaction":"SICKLE CELL ANAEMIA WITH CRISIS"},{"count":1111,"reaction":"FATIGUE"},{"count":1098,"reaction":"DIARRHOEA"},{"count":990,"reaction":"NAUSEA"},{"count":814,"reaction":"HEADACHE"},{"count":751,"reaction":"DEATH"},{"count":739,"reaction":"PRODUCT DOSE OMISSION ISSUE"},{"count":702,"reaction":"DRUG INEFFECTIVE"},{"count":676,"reaction":"HAEMOGLOBIN DECREASED"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"💊","route":"Oral","frequency":"once daily","formulation":"capsule"},"crossReferences":{"chemblId":"CHEMBL467"},"formularyStatus":[],"_approvalHistory":[{"date":"20240306","type":"ORIG","sponsor":"QILU","applicationNumber":"ANDA218021"},{"date":"20000921","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA075143"},{"date":"19990513","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA075143"},{"date":"19990520","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA075143"},{"date":"20240923","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA075143"},{"date":"20240923","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA075143"},{"date":"20130227","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA075143"},{"date":"20111114","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA075143"},{"date":"20240923","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA075143"},{"date":"20010927","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA075143"},{"date":"19991221","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA075143"},{"date":"20000921","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA075143"},{"date":"19990513","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA075143"},{"date":"19990323","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA075143"},{"date":"19981016","type":"ORIG","sponsor":"BARR","applicationNumber":"ANDA075143"},{"date":"20240923","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA075143"},{"date":"20240923","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA075143"},{"date":"20130227","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA075143"},{"date":"20240923","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA075143"},{"date":"20060815","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA075143"},{"date":"20240923","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA075143"},{"date":"20050428","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA075143"},{"date":"20000524","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA075143"},{"date":"20240409","type":"SUPPL","sponsor":"LEADING","applicationNumber":"ANDA213438"},{"date":"20200408","type":"ORIG","sponsor":"LEADING","applicationNumber":"ANDA213438"},{"date":"20240409","type":"SUPPL","sponsor":"LEADING","applicationNumber":"ANDA213438"},{"date":"20130227","type":"SUPPL","sponsor":"PH HEALTH","applicationNumber":"ANDA075340"},{"date":"20110411","type":"SUPPL","sponsor":"PH HEALTH","applicationNumber":"ANDA075340"},{"date":"20060815","type":"SUPPL","sponsor":"PH HEALTH","applicationNumber":"ANDA075340"},{"date":"20010327","type":"SUPPL","sponsor":"PH HEALTH","applicationNumber":"ANDA075340"},{"date":"20111011","type":"SUPPL","sponsor":"PH HEALTH","applicationNumber":"ANDA075340"},{"date":"20150120","type":"SUPPL","sponsor":"PH HEALTH","applicationNumber":"ANDA075340"},{"date":"19990224","type":"ORIG","sponsor":"PH HEALTH","applicationNumber":"ANDA075340"},{"date":"20020411","type":"SUPPL","sponsor":"PH HEALTH","applicationNumber":"ANDA075340"}],"developmentCodes":[],"ownershipHistory":[{"notes":"","period":"Unknown–present","companyName":"Unknown","relationship":"Originator"}],"publicationCount":11263,"therapeuticAreas":["Oncology"],"trialPhaseCounts":{"":8,"PHASE1":7,"PHASE2":14,"PHASE3":8,"PHASE4":5,"PHASE1, PHASE2":7,"PHASE2, PHASE3":1},"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"approved","brandName":"HYDROXYUREA","genericName":"HYDROXYUREA","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"1967","aiSummary":"","enrichmentLevel":4,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1988-08-25T00:00:00.000Z","mah":"WAYLIS THERAP","brand_name_local":null,"application_number":"NDA016295"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2000-05-24T00:00:00.000Z","mah":"BARR","brand_name_local":null,"application_number":"ANDA075143"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2021-12-07T00:00:00.000Z","mah":"THERAVIA","brand_name_local":null,"application_number":"NDA208843"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-03-06T00:00:00.000Z","mah":"QILU","brand_name_local":null,"application_number":"ANDA218021"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-04-09T00:00:00.000Z","mah":"LEADING","brand_name_local":null,"application_number":"ANDA213438"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"patentsNormalised":[{"patent_number":"12409156","territory":"US","patent_type":"Formulation","expiry_date":"2041-12-23T00:00:00.000Z","status":"active","paragraph_iv_filed":false}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:33:56.108818+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}